Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI FOLFOX for Liver-Predominant Metastatic Breast Cancer
NCT01937507Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Dec 2012
- Primary completion
- Jul 2014
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in breast cancer, sponsored by Western Regional Medical Center. Primary endpoints: Response Rate at 1 year, Time to Intra-hepatic Progression at 1 year and 1 more. Started Dec 2012; status: terminated.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01937507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01937507.